

## Cell Line Data Sheet for SMS-KCNR

**Disease:** Neuroblastoma  
**Phase of Therapy:** Post-Chemotherapy (Progressive Disease)  
**Treatment:** Doxorubicin, cyclophosphamide  
**Disease Stage:** 4  
**Gender:** Male  
**Age at diagnosis:** 11 months  
**Race:** N/A  
**Age at sample collection:** N/A  
**Source of Culture:** Bone Marrow  
**Primary Tumor Site:** Adrenal gland  
**Date Established:** November 1979

**MYCN Patient:** Amplified  
**MYCN Cell line:** N/A  
**TH mRNA:** Positive  
**p53 functionality:** Functional  
**Telomere Mechanism** N/A  
**ALK:** F1174L

|                         |                      |                     |                    |                     |                      |
|-------------------------|----------------------|---------------------|--------------------|---------------------|----------------------|
| <b>IC90 (DIMSCAN*):</b> | <u>CBDCA (µg/ml)</u> | <u>CDDP (µg/ml)</u> | <u>DOX (ng/ml)</u> | <u>ETOP (ng/ml)</u> | <u>L-PAM (µg/ml)</u> |
| *see reference 4        | 1.9                  | 0.3                 | 17                 | 10.5                | 3.8                  |

CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan

**Growth Conditions:** Please see Protocols section at <https://www.cccells.org/protocols.php>  
5% CO<sub>2</sub>, 20% O<sub>2</sub>, 37.0°C

**Media Formulation:** Please see Protocols section at <https://www.cccells.org/protocols.php>  
Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

**Doubling Time:** 72 hours  
**Growth Properties:** Round, teardrop-shaded neuroblasts, adherent and suspended cells, grow mostly in clumps

**STR Profile:** May be obtained at <https://strdb.cccells.org/>

**Notes:**

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

---

## Cell Line Data Sheet for SMS-KCNR

---

### References:

1. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG: Characterization of human neuroblastoma cell lines established before and after therapy. *J Natl Cancer I.* 76:375-387, 1986. PubMed ID: 3546456  
<https://www.sciencedirect.com/science/article/pii/S0002817787420187?via%3Dihub>
2. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds C P: Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. *Cancer Res.* 61:6185-6193, 2001. PubMed ID: 11507071  
<https://cancerres.aacrjournals.org/content/61/16/6185.long>
3. Reynolds CP, Brodeur GM, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ: Biological classification of cell lines derived from human extra-cranial neural tumors. *Prog Clin Biol Res.* 271:291-306, 1988. PubMed ID: 3406003
3. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. *Cancer Research.* 58:5396-5405, 1998. PubMed ID: 9850071  
<https://cancerres.aacrjournals.org/content/58/23/5396.long>
4. Wang Y, Einhorn P, Triche TJ, Seeger RC, Reynolds CP. Expression of Protein Gene Product 9.5 and Tyrosine Hydroxylase in Childhood Small Round Cell Tumors. *Clin Cancer Res.* 6, 551-558, 2000. PubMed ID: 10690538  
<https://clincancerres.aacrjournals.org/content/6/2/551.long>
5. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. *Cancer Chemoth Pharm.* 45: 1-8, 2000. PubMed ID: 10647494  
<https://link.springer.com/article/10.1007%2FPL00006736>
6. Frgala T, Kalous O, Proffitt RT, Reynolds CP: A novel cytotoxicity assay with a 4 log dynamic range that identifies synergistic drug combinations. *Mol Cancer Ther.* 6:886-89, 2007. PubMed ID: 17363483  
<https://mct.aacrjournals.org/content/6/3/886.long>
7. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide. *J Natl Cancer I.* 99: 1107-19, 2007. PubMed ID: 17623797  
<https://academic.oup.com/jnci/article/99/14/1107/938992>

8. Maurer BJ, Kalous O, Yesair DW, Wu X, Vratilova J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP: Improved oral delivery of N-(4-hydroxyphenyl)retinamide with novel LYM-X-SORBTM organized lipid complex in mice. Clin Cancer Res. 13:3079-3086, 2007. PubMed ID: 17505011  
<https://clincancerres.aacrjournals.org/content/13/10/3079.long>

---

Childhood Cancer Repository  
Powered by Alex's Lemonade Stand  
COG resource Laboratory  
[www.ccells.org](http://www.ccells.org)

2 / 3



---

## Cell Line Data Sheet for SMS-KCNR

---

**Cell Line Name:** SMS-KCNR

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)

---

Childhood Cancer Repository  
Powered by Alex's Lemonade Stand  
COG resource Laboratory

[www.ccells.org](http://www.ccells.org)



3 / 3

